Sai Life Sciences Share Price Target 2026 Analyst Forecast Bull and Bear Case

Sai Life Sciences (NSE: SAILIFE) is a Pharmaceutical CDMO and API Services company trading at Rs 1,222 with a market capitalisation of Rs 25,614 crore. Analysts have set the Sai Life Sciences share price target at Rs 1,450 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Sai Life Sciences Share Price Target 2026: Key Takeaways

• Sai Life Sciences share price target 2026: Rs 1,450 (20% upside from CMP Rs 1,222)
• Bull case: Rs 1,750 | Bear case: Rs 975
• Ticker: SAILIFE | Sector: Pharmaceutical CDMO and API Services | MCap: Rs 25,614 crore
• 52W range: Rs 744.1 to Rs 1,249 | PE: 40x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Sai Life Sciences Company Overview

Sai Life Sciences (NSE: SAILIFE) is a Hyderabad-based pharmaceutical CDMO listed in 2024, providing integrated drug discovery, development, and manufacturing services to global innovator pharma companies. At CMP Rs 1,222 against a 52 week range of Rs 744.1 to Rs 1,249, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 25,614 crore with trailing PE of 40x. Compared to peers in CDMO like Divi’s Laboratories and Syngene International, Sai Life Sciences is positioned as a potential re-rating candidate toward the Rs 1,450 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	SAILIFE
Sector	Pharmaceutical CDMO and API Services
CMP (2026)	Rs 1,222
52 Week High	Rs 1,249
52 Week Low	Rs 744.1
Market Cap	Rs 25,614 crore
Trailing PE	40x
12-Month Analyst Target	Rs 1,450
Bull Case Target	Rs 1,750
Bear Case Target	Rs 975

Why Is the Sai Life Sciences Share Price Target Set at Rs 1,450 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Sai Life Sciences share price target of Rs 1,450 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 1,222.

Structural Sector Tailwinds in Pharmaceutical CDMO and API Services

The Pharmaceutical CDMO and API Services sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Sai Life Sciences’s position among peers in CDMO like Divi’s Laboratories and Syngene International creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 1,750 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Sai Life Sciences’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,450 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Sai Life Sciences’s Pharmaceutical CDMO and API Services operations, improving the probability of achieving the Rs 1,450 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 40x PE, Sai Life Sciences is positioned as a beneficiary of institutional reallocation toward the Rs 1,750 bull case over the medium term.

Sai Life Sciences Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Sai Life Sciences Share Price Target

Near-term support for Sai Life Sciences is anchored close to the 52 week low of Rs 744.1. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 1,222.

12-Month Sai Life Sciences Share Price Target 2026

The 12-month Sai Life Sciences share price target 2026 is Rs 1,450, implying approximately 20 percent upside from CMP Rs 1,222. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Sai Life Sciences Share Price Target: FY27 to FY28

The long term Sai Life Sciences share price target for FY27 to FY28 is Rs 1,750 in the bull case, requiring full earnings delivery, re-rating among peers in CDMO like Divi’s Laboratories and Syngene International, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Sai Life Sciences in 2026

Bull Case Sai Life Sciences Share Price Target: Rs 1,750

The bull case Sai Life Sciences share price target of Rs 1,750 materialises when FY27 earnings beat analyst estimates, Pharmaceutical CDMO and API Services tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 1,222.

Bear Case Sai Life Sciences Share Price Target: Rs 975

The bear case Sai Life Sciences share price target of Rs 975 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 744.1.

Scenario	Target	Key Conditions
Bull Case	Rs 1,750	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 1,450	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 975	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Sai Life Sciences 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Sai Life Sciences share price target of Rs 1,450, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,450 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical CDMO and API Services Peers

Intensifying competition from peers in CDMO like Divi’s Laboratories and Syngene International could compress Sai Life Sciences’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,450 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Sai Life Sciences

Check the Univest Screener for live data

Before considering any investment based on the Sai Life Sciences share price target of Rs 1,450, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical CDMO and API Services sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Sai Life Sciences (NSE: SAILIFE) with full regulatory protection. Study the competitive landscape among peers in CDMO like Divi’s Laboratories and Syngene International before executing any position.

Plan your entry using the 52 week low of Rs 744.1 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,450 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Sai Life Sciences’s live share price and receive daily stock recommendations.

FAQs on Sai Life Sciences Share Price Target 2026

What is the Sai Life Sciences share price target for 2026?

Ans. The Sai Life Sciences share price target 2026 is Rs 1,450, implying approximately 20 percent upside from CMP Rs 1,222. Bull case is Rs 1,750, bear case is Rs 975.

What was the Sai Life Sciences share price target for 2025?

Ans. The 2025 price objective for Sai Life Sciences was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,450, reflecting FY27 growth potential from CMP Rs 1,222.

Is Sai Life Sciences a good investment at Rs 1,222?

Ans. At Rs 1,222, Sai Life Sciences offers potential upside toward Rs 1,450 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Sai Life Sciences share price target 2026?

Ans. Key risks to the Sai Life Sciences share price target of Rs 1,450 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical CDMO and API Services. Monitoring quarterly results is essential.

What is the 52 week high and low of Sai Life Sciences?

Ans. The 52 week high of Sai Life Sciences is Rs 1,249 and the 52 week low is Rs 744.1. At CMP Rs 1,222, the stock offers potential upside toward the Rs 1,450 price objective.

What are the main growth catalysts for Sai Life Sciences in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical CDMO and API Services tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Sai Life Sciences compare to its peers?

Ans. Sai Life Sciences operates in Pharmaceutical CDMO and API Services alongside peers in CDMO like Divi’s Laboratories and Syngene International. At CMP Rs 1,222 with MCap Rs 25,614 crore, it is a potential re-rating candidate toward the Sai Life Sciences share price target of Rs 1,450 on FY27 delivery.

What is the Sai Life Sciences share price target for 2027?

Ans. The long-term Sai Life Sciences share price target for FY27 to FY28 is Rs 1,750 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.